Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...
Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...
Katie Swicegood Fulp is a bit of a late arrival to the world of pharma marketing. | In a Q&A for Fierce Pharma Marketing’s ...
In just its fifth full quarter on the market, the world’s first treatment for metabolic dysfunction-associated ...
The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...
Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). | Teva Pharmaceuticals has a new ...
Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that ...
With its biosimilars business thriving, Amgen isn’t a fan of changes proposed by HHS Secretary Robert F. Kennedy Jr. | With its biosimilars business thriving, Amgen isn’t a fan of changes proposed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback